Alnylam Pharmaceuticals(US:ALNY)2022-07-28 18:11Financial Performance - Alnylam's Q2 2022 net product revenues reached $214 million, a 33% increase compared to $161 million in Q2 2021[48] - At constant exchange rates (CER), total net product revenue growth was 40%[48] - ONPATTRO global Q2 2022 net product revenues were $153 million[17] - GIVLAARI global Q2 2022 net product revenues were $52 million[23] - OXLUMO global Q2 2022 net product revenues were $9 million[27] Product Growth - ONPATTRO experienced a 35% year-over-year (YoY) global growth and 12% quarter-over-quarter (QoQ) growth[19] - GIVLAARI showed a 47% YoY global growth and 28% QoQ growth[25] - OXLUMO had a -9% YoY global growth but a 2% QoQ growth[29] 2022 Financial Guidance - The company reiterated its 2022 net product revenue guidance of $870 million to $930 million[49] - Net revenues from collaborations and royalties are expected to be between $175 million and $225 million[49] - Non-GAAP combined R&D and SG&A expenses are projected to be $1390 million to $1450 million[49]